Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | PTGIR | P43119 | 6/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.32 |
| ▸ | ATF4 | P18848 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913660 | 1.00 | ITGB3 (0.38) | ITGB3ITGA2BTHRATHRBPTGIR | |
| SCHEMBL18674316 | 1.00 | ITGB3 (0.38) | ITGB3ITGA2BTHRATHRBPTGIR | |
| SCHEMBL30962323 | 1.00 | ITGB3 (0.38) | ITGB3ITGA2BTHRATHRBPTGIR | |
| SCHEMBL11918037 | 1.00 | ITGB3 (0.38) | ITGB3ITGA2BTHRATHRBPTGIR | |
| SCHEMBL461965 | 1.00 | ITGB3 (0.38) | ITGB3ITGA2BTHRATHRBPTGIR | |
| Hydrochloric Acid SCHEMBL22635011 | 0.98 | ITGB3 (0.38) | ITGB3ITGA2BTHRATHRBPTGIR | |
| SCHEMBL360541 | 0.83 | ITGB3 (0.41) | ITGB3ITGA2BTHRATHRBPTGIR | |
| SCHEMBL1733927 | 0.83 | — | — | |
| SCHEMBL22635010 | 0.83 | ATF4 (0.33) | ATF4 | |
| SCHEMBL22635009 | 0.83 | ATF4 (0.33) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038748-A1 | Compositions And Methods For In Vivo Imaging | THE GENERAL HOSPITAL CORPORATION | 2021-02-11 | — | — | US | disclosed |
| US-10653805-B2 | Compositions and methods for in vivo imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-10434197-B2 | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes | UNIVERSITY OF DELAWARE (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190201562-A1 | Compositions And Methods For In Vivo Imaging | THE GENERAL HOSPITAL CORPORATION | 2019-07-04 | — | — | US | disclosed |
| US-10117954-B2 | Compositions and methods for in vivo imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180015186-A1 | Compositions And Methods For In Vivo Imaging | THE GENERAL HOSPITAL CORPORATION | 2018-01-18 | — | — | US | disclosed |
| US-20180015186-A1 | Compositions And Methods For In Vivo Imaging | THE GENERAL HOSPITAL CORPORATION | 2018-01-18 | — | — | US | disclosed |
| US-9649394-B2 | Compositions and methods for in vivo imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649394-B2 | Compositions and methods for in vivo imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649394-B2 | Compositions and methods for in vivo imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-20130309170-A1 | Compositions And Methods For In Vivo Imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2654796-A1 | AGENTS FOR CLEARING BIOMOLECULES FROM CIRCULATION | Koninklijke Philips N.V. (NL) | 2013-10-30 | — | — | EP | disclosed |
| US-20130266512-A1 | Tetrazine-trans-cyclooctene Ligation for the Rapid Construction of Radionuclide Labeled Probes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2595967-A2 | TETRAZINE-TRANS-CYCLOOCTENE LIGATION FOR THE RAPID CONSTRUCTION OF RADIONUCLIDE LABELED PROBES | University Of Delaware (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012085789-A1 | AGENTS FOR CLEARING BIOMOLECULES FROM CIRCULATION | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012074840-A2 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074840-A2 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012012612-A2 | TETRAZINE-TRANS-CYCLOOCTENE LIGATION FOR THE RAPID CONSTRUCTION OF RADIONUCLIDE LABELED PROBES | UNIVERSITY OF DELAWARE (US) | 2012-01-26 | — | — | WO | disclosed |
| US-4780564-A | PERFUMES, COSMETICS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1988-10-25 | — | — | US | disclosed |
| US-4755502-A | Allyl-4-cyclooctenyl glycolate, organoleptic uses thereof, process for preparing same and intermediates useful in said process | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1988-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015186-A1 | Compositions And Methods For In Vivo Imaging | PARP1, PARP11, PARP2 | ITGB3 109/4885ITGA2B 429/4885THRA 4667/4885 |
| US-20210038748-A1 | Compositions And Methods For In Vivo Imaging | PARP1, PARP11, PARP2 | ITGB3 109/4885ITGA2B 429/4885THRA 4667/4885 |
| US-20130309170-A1 | Compositions And Methods For In Vivo Imaging | PARP1, PARP11, PARP2 | ITGB3 109/4885ITGA2B 429/4885THRA 4667/4885 |
| US-10434197-B2 | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes | TTL, TALDO1, TTI1 | ITGB3 2868/4885ITGA2B 2932/4885THRA 160/4885 |
| US-10653805-B2 | Compositions and methods for in vivo imaging | PARP1, PARP11, PARP2 | ITGB3 109/4885ITGA2B 429/4885THRA 4667/4885 |
| US-10117954-B2 | Compositions and methods for in vivo imaging | PARP1, PARP11, PARP2 | ITGB3 109/4885ITGA2B 429/4885THRA 4667/4885 |
| US-20130266512-A1 | Tetrazine-trans-cyclooctene Ligation for the Rapid Construction of Radionuclide Labeled Probes | TTL, TALDO1, TTI1 | ITGB3 2868/4885ITGA2B 2932/4885THRA 160/4885 |
| US-20190201562-A1 | Compositions And Methods For In Vivo Imaging | PARP1, PARP11, PARP2 | ITGB3 109/4885ITGA2B 429/4885THRA 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.